Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
15 October, 2024
Diversity, equity and inclusion at heart of TROG work
15 October 2024: TROG Cancer Research has made a
1 October, 2024
A plan for the future of cancer research
12 September 2024: TROG Cancer Research has outlined how
